← Back to all trials
Completed
NCT07303907
A Phase 2A Trial of DT402 for Autism Spectrum Disorder
Conditions: Autism Spectrum Disorder, ASD
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 5
Sponsor: Definium Therapeutics US, Inc.
Location: Spectrum Neuroscience and Treatment Institute New York New York
Summary
A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder
Eligibility Criteria
Inclusion Criteria:
1. Diagnosis of ASD per records as confirmed by standard semi-structured interview for Autism diagnosis (eg, Autism Diagnostic Observation Schedule-Second Edition)
2. Male or Female aged 18 to 65
3. Presents with clinically significant deficits in socialization and communication as determined by Social Responsiveness Scales (SRS-2) ≥66
Exclusion Criteria:
1. Has uncorrected abnormalities in eye movement, alignment, or acuity or atypical eye features that could interfere with eye tracking
2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
4. Any clinically significant unstable illness
Source: ClinicalTrials.gov (NCT07303907). StuddyBuddy aggregates publicly available trial information.
